Home > Escp Profiles > bioXclusters plus

bioXclusters plus

Primary tabs

Name: 
ESCP on Personalised Healthcare
Acronym: 
bioXclusters plus
ESCP-4i Status: 
Implementation Phase - Strand2
Start of Partnership: 
Friday, 1 January, 2016
Previous initiatives: 
European Cluster Consortia 2012: 
bioXclusters
ESCP Pilots 2013: 
Healthcare
ESCP-4i Charter: 
Partnership duration
24 months
Number of partners
4
Number of SMEs involved
880
Targeted third countries
Australia
Brazil
Canada
China
Japan
Republic of Korea (South Korea)
United States

The bioXclusters+ alliance, supported from 2016 to 2018, gathers 4 European Life Sciences / health clusters: Biocat (Catalonia), BioM (Bavaria), BioPmed (Piedmont), Lyonbiopole (Auvergne Rhone-Alpes). It aims to address the next-decade European challenges related to healthcare and SMEs growth, thanks to a common vision of personalised healthcare as the paradigm for future global healthcare solutions. To address this new paradigm, the bioXclusters+ partnership intends to be the most competitive European meta-cluster initiative in personalised healthcare, delivering at global level cutting edge solutions through its innovation ecosystem and offering an entry point for global players to Europe. In this regard, the consortium internationalisation strategy plan to focus their activities on three countries already explored (US, China and Brazil) but also on additional markets such as Japan. The approach consists in confirming its position at European and international scene in gaining visibility inside and outside Europe; reinforcing trustful relations with target countries building Gateways; deploy common internationalisation tools and tailored supported to European SMEs based on the mutual competence knowledge and long term relationship developed within the alliance. Furthermore the alliance will focus their action on addressing the challenges related to the global healthcare sector, such as the inclusion of technologies such as big data, micro and nanotechnologies, ICT for the development of systemic and practical solutions addressing the industry competitiveness and the patients' needs. This is the reason why collaboration with other key players (such as other ESCPs and other EU initiatives) in the sector mentioned above will be deploy.

Sectoral Industries: 
Biopharmaceuticals
Technology Fields: 
BIOLOGICAL SCIENCESMedicine, Human HealthPharmaceutical Products / Drugs
S3 EU priority areas: 
Human health & social work activities:Human health activities (medical services)
Emerging industries: 
Bio-pharmaceuticals
Other: 

Development of Healthcare solutions and products (innovative targeted therapies, diagnostic tools and solutions, e-health solutions...)

Partnership planned events: 
Target GroupTypeEstimated DateCountryCity
Cluster Organisations
Open to SMEs
Matchmaking Event
10/11/2016
Japan
Osaka
Cluster Organisations
Matchmaking Event
11/08/2016
Germany
Cologne
Cluster Organisations
Matchmaking Event
06/08/2016
United States
San Francisco
Open to SMEs
Training
10/10/2016
Japan
Osaka
Cluster Organisations
Open to SMEs
Matchmaking Event
03/20-21/2017
Spain
Barcelona
Cluster Organisations
Conference
10/13/2016
Japan
Yokohama
Cluster Organisations
Open to SMEs
Matchmaking Event
15-17/05/2017
China
Shanghai
Cluster Organisations
Open to SMEs
Matchmaking Event
10/10/2017
Japan
Osaka
Partnership other activities: 
  1. Meta-cluster marketing and communication Shaping
  2. Reinforcing and building gateways to third countries including a cross-sectoral dimension
  3. Tailoring tools and services for SMEs (information package, missions abroad, B2B meetings...)
  4. Monitoring activities and indicators

 

Signature of MoUs and gateways agreements with third countries

Organisation of C2C and B2B meetings

Organisation of inbound and outbound missions

Increase of collaborations with SMEs and external partners (technological and commercial agreements)

Other key partners or networks your partnership is linked with in Europe and in third countries: 
CountryNameLink
Belgium
CEBR
Australia
BioSA and Health Industries South Australia
Japan
Osaka Bio Headquarters
Republic of Korea (South Korea)
Chuncheon Bioindustry Foundation
China
Fenglin Group
Canada
ToHealth!
United States
Wistar Institute

Partnership composition

Name Sector/Technology fields Country Regions Total no. of members Total no. of SME
bioPmed / Bioindustry Park Biopharmaceuticals, Business Services

Diagnostics, Diagnosis, Medical Technology / Biomedical Engineering, Pharmaceutical Products / Drugs

Public health and securityAgeing societies, Public health and securityPublic health and well-being, ServicesScientific research & development

Bio-pharmaceuticals, Medical Devices
Italy Piemonte 70 55
Biocat (Bioregion of Catalonia) Biopharmaceuticals, Education and Knowledge Creation

Digital Agendae-Health (e.g. healthy ageing), Human health & social work activities:Human health activities (medical services), Public health and securityPublic health and well-being

Bio-pharmaceuticals, Medical Devices
Spain Cataluña 734 500
BioM Biotech Cluster Development GmbH Biopharmaceuticals

Diagnostics, Diagnosis, Pharmaceutical Products / Drugs

Digital Agendae-Health (e.g. healthy ageing), KETSIndustrial biotechnology, Manufacturing & IndustryBiotechnology

Bio-pharmaceuticals, Digital Industries, Medical Devices
Germany Oberbayern 347 170
LYONBIOPOLE Biopharmaceuticals

Cellular and Molecular Biology, Health information management, Diagnostics, Diagnosis

Digital Agendae-Health (e.g. healthy ageing), Human health & social work activities:Human health activities (medical services), KETSIndustrial biotechnology

Bio-pharmaceuticals, Digital Industries, Medical Devices
France Rhône-Alpes 200 160